Literature DB >> 1752740

Aminoglycoside induced ototoxicity in patients with cystic fibrosis.

D Mulherin1, J Fahy, W Grant, M Keogan, B Kavanagh, M FitzGerald.   

Abstract

The improved survival of cystic fibrosis (CF) patients is partly due to intensive treatment for their chronic infections. Treatment usually includes intravenous and nebulised aminoglycoside antibiotics and they receive a large cumulative dose of these antibiotics over their lifetime. There is little information in the literature on the prevalence of ototoxicity due to aminoglycoside in these patients. We performed pure tone audiometry on 43 CF patients aged 14-42 years. Seven (16%) had bilateral sensorineural hearing loss (SNHL) for high frequency sounds, consistent with aminoglycoside induced ototoxicity. However, only 2 of these patients had documented toxic serum levels in the past. The identification of bilateral SNHL in one in six adult CF patients is a cause for concern. It may be that the high cumulative dose of aminoglycosides received by these patients may be causing inner ear injury in the absence of specific episodes of toxic serum levels.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1752740     DOI: 10.1007/bf02961666

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  11 in total

1.  A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis.

Authors:  L E GIBSON; R E COOKE
Journal:  Pediatrics       Date:  1959-03       Impact factor: 7.124

2.  Ototoxic mechanisms. A working hypothesis.

Authors:  E Hawkins
Journal:  Audiology       Date:  1973 Sep-Dec

3.  Inner ear concentrations and ototoxicity of different antibiotics in local and systemic application.

Authors:  H Stupp; K Küpper; F Lagler; H Sous; M Quante
Journal:  Audiology       Date:  1973 Sep-Dec

4.  Cystic fibrosis mortality in England and Wales and in Victoria, Australia 1976-80.

Authors:  P Phelan; E Hey
Journal:  Arch Dis Child       Date:  1984-01       Impact factor: 3.791

5.  Ototoxicity of aminoglucoside antibiotics in long-term treatment for cystic fibrosis.

Authors:  S Crifo; M Antonelli; M Gagliardi; N Lucarelli; P Marcolini
Journal:  Int J Pediatr Otorhinolaryngol       Date:  1980-09       Impact factor: 1.675

6.  Pharmacokinetics of tobramycin in cystic fibrosis.

Authors:  H B Kelly; R Menendez; L Fan; S Murphy
Journal:  J Pediatr       Date:  1982-02       Impact factor: 4.406

Review 7.  Randomized trials of aminoglycoside antibiotics: quantitative overview.

Authors:  J E Buring; D A Evans; S L Mayrent; B Rosner; T Colton; C H Hennekens
Journal:  Rev Infect Dis       Date:  1988 Sep-Oct

8.  Cystic fibrosis in adolescents and adults.

Authors:  A R Penketh; A Wise; M B Mearns; M E Hodson; J C Batten
Journal:  Thorax       Date:  1987-07       Impact factor: 9.139

9.  Dosing implications of altered gentamicin disposition in patients with cystic fibrosis.

Authors:  G L Kearns; B C Hilman; J T Wilson
Journal:  J Pediatr       Date:  1982-02       Impact factor: 4.406

10.  Prevalence and survival of patients with cystic fibrosis in Northern Ireland, 1961-1971.

Authors:  G B Nevin; N C Nevin; A O Redmond
Journal:  Ulster Med J       Date:  1983
View more
  11 in total

Review 1.  Systematic reviews and lifelong diseases.

Authors:  Heather E Elphick; Anton Tan; Deborah Ashby; Rosalind L Smyth
Journal:  BMJ       Date:  2002-08-17

Review 2.  Drug-Induced Ototoxicity: Diagnosis and Monitoring.

Authors:  Kathleen C M Campbell; Colleen G Le Prell
Journal:  Drug Saf       Date:  2018-05       Impact factor: 5.606

3.  [Routine otorhinolaryngological examination in patients with cystic fibrosis].

Authors:  A Koitschev; A Wolff; C Koitschev; S Preyer; R Ziebach; M Stern
Journal:  HNO       Date:  2006-05       Impact factor: 1.284

Review 4.  Single versus combination intravenous anti-pseudomonal antibiotic therapy for people with cystic fibrosis.

Authors:  Heather E Elphick; Alison Scott
Journal:  Cochrane Database Syst Rev       Date:  2016-12-01

5.  Occurrence and risk of cochleotoxicity in cystic fibrosis patients receiving repeated high-dose aminoglycoside therapy.

Authors:  M Mulheran; C Degg; S Burr; D W Morgan; D E Stableforth
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

Review 6.  The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?

Authors:  D Banerjee; D Stableforth
Journal:  Drugs       Date:  2000-11       Impact factor: 9.546

Review 7.  Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions.

Authors:  D J Touw; A A Vinks; J W Mouton; A M Horrevorts
Journal:  Clin Pharmacokinet       Date:  1998-12       Impact factor: 6.447

8.  Assessment of nutrient supplement to reduce gentamicin-induced ototoxicity.

Authors:  C G Le Prell; C Ojano-Dirain; E W Rudnick; M A Nelson; S J DeRemer; D M Prieskorn; J M Miller
Journal:  J Assoc Res Otolaryngol       Date:  2014-03-04

9.  Does amikacin treatment cause subclinical hearing loss in patients with cystic fibrosis?

Authors:  Fevzi Solmaz; Ercan Gündoğdu; Davut Akduman; Mehmet Haksever; Oğuzhan Dikici; Fatih Ünal
Journal:  Toxicol Rep       Date:  2016-03-22

10.  Single versus combination intravenous anti-pseudomonal antibiotic therapy for people with cystic fibrosis.

Authors:  Poppy Holland; Nikki Jahnke
Journal:  Cochrane Database Syst Rev       Date:  2021-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.